Breast Neoplasms: Tumors or cancer of the human BREAST.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Breast Diseases: Pathological processes of the BREAST.Breast Feeding: The nursing of an infant at the breast.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Breast Neoplasms, Male: Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.Cell Line, Tumor: A cell line derived from cultured tumor cells.Mammography: Radiographic examination of the breast.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Fibrocystic Breast Disease: A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.Receptors, Progesterone: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Breast Implants: Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Breast Self-Examination: The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Mastectomy: Surgical procedure to remove one or both breasts.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Antineoplastic Agents, Hormonal: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)Ultrasonography, Mammary: Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Genes, BRCA1: A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Proportional Hazards Models: Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Postmenopause: The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Mastectomy, Segmental: Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Breast Cyst: A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.Estrogen Receptor alpha: One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.Milk, HumanMammaplasty: Surgical reconstruction of the breast including both augmentation and reduction.Mammary Glands, Human: Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.MCF-7 Cells: An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Estrogens: Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.Fibroadenoma: An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)Premenopause: The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Axilla: Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.Genes, erbB-2: The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Nipples: The conic organs which usually give outlet to milk from the mammary glands.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.Breast Implantation: Surgical insertion of an inert sac filled with silicone or other material to augment the female form cosmetically.BRCA2 Protein: A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Neoplasms, Hormone-Dependent: Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.Genetic Predisposition to Disease: A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)DNA, Neoplasm: DNA present in neoplastic tissue.BRCA1 Protein: The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Lung Neoplasms: Tumors or cancer of the LUNG.Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Genes, BRCA2: A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)Inflammatory Breast Neoplasms: Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.Risk: The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Biopsy, Needle: Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Estrogen Antagonists: Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Aromatase Inhibitors: Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Mass Screening: Organized periodic procedures performed on large groups of people for the purpose of detecting disease.Reproducibility of Results: The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Gene Amplification: A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Odds Ratio: The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.Estradiol: The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.RNA, Neoplasm: RNA present in neoplastic tissue.Mastectomy, Modified Radical: Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Registries: The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.Recurrence: The return of a sign, symptom, or disease after a remission.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Liver Neoplasms: Tumors or cancer of the LIVER.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Logistic Models: Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.Selective Estrogen Receptor Modulators: A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Transplantation, Heterologous: Transplantation between animals of different species.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.DNA Methylation: Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.Genotype: The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Lymph Node Excision: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Adenofibroma: A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)Germ-Line Mutation: Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)United StatesColorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Polymorphism, Single Nucleotide: A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.Promoter Regions, Genetic: DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.Stomach Neoplasms: Tumors or cancer of the STOMACH.Nitriles: Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.Antigens, CD24: A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.Neoplastic Cells, Circulating: Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.Chi-Square Distribution: A distribution in which a variable is distributed like the sum of the squares of any given independent random variable, each of which has a normal distribution with mean of zero and variance of one. The chi-square test is a statistical test based on comparison of a test statistic to a chi-square distribution. The oldest of these tests are used to detect whether two or more population distributions differ from one another.Questionnaires: Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Epithelial Cells: Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.Polymorphism, Genetic: The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.Sentinel Lymph Node Biopsy: A diagnostic procedure used to determine whether LYMPHATIC METASTASIS has occurred. The sentinel lymph node is the first lymph node to receive drainage from a neoplasm.Neoplasms, Basal Cell: Neoplasms composed of cells from the deepest layer of the epidermis. The concept does not refer to neoplasms located in the stratum basale.Parity: The number of offspring a female has borne. It is contrasted with GRAVIDITY, which refers to the number of pregnancies, regardless of outcome.SEER Program: A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)Neoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Repulsive guidance molecule B"Entrez Gene: RGM domain family". Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, ... Li J, Ye L, Sanders AJ, Jiang WG (March 2012). "Repulsive guidance molecule B (RGMB) plays negative roles in breast cancer by ... The perturbed expression was associated with disease progression and poor prognosis. GRCh38: Ensembl release 89: ... Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat ...
Kang Y (Jan 2009). "MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast ... Wang S, Shu JZ, Cai Y, Bao Z, Liang QM (2012). "Establishment and characterization of MTDH knockdown by artificial MicroRNA ... Elevated expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers, is ... Brown DM, Ruoslahti E (Apr 2004). "Metadherin, a cell surface protein in breast tumors that mediates lung metastasis". Cancer ...
"Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer". Journal of Cancer ... Ling SB, Sun DG, Tang B, Guo C, Zhang Y, Liang R, Wang LM (December 2012). "Knock-down of USP22 by small interfering RNA ... Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S, Pang D (August 2011). " ... "Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer". Journal of Surgical ...
Kentucky then played in the Outback Bowl, Kentucky's first New Year's Day bowl in 47 years. Despite jumping out to a 14-3 lead ... His wife, June, is a breast cancer survivor and is active with the Susan G. Komen Foundation. Mumme has two daughters and a son ... Mumme was diagnosed with prostate cancer in early 2009; the cancer was reportedly caught early and his prognosis is good. ... Kentucky had gone 9-24 (.273) through the prior three years. In Mumme's first year the team improved to a 5-6 record. The ...
"Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data". BMC ... Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A ... 2008 Aug;9(5):349-60.PMID 19517027 Liu J, Campen A, Huang S, Peng SB, Ye X, Palakal M, Dunker AK, Xia Y, Li S (Sep 2008). " ... The applications of these prognostic signatures include prognostic assays for breast cancer, hepatocellular carcinoma, ...
2009). Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of ... doi:10.1152/ajpheart.00081.2004 Chuong, C.J. and Fung, Y.C. (1986). On residual stress in arteries. Journal of Biomechanics 108 ... doi:10.1242/dev.02883 Castier, Y. et al. (March, 2009). Role of NF-κB in flow-induced vascular remodelling. Antioxidants & ... ISBN 978-92-4-156437-3 Castier, Y. et al. (August, 2005). p47phox-dependent NADPH oxidase regulates flow-induced vascular ...
They generally have a good prognosis. In one larger study, the 5-year and 10-year survival were over 90% and 80% respectively. ... Its appearance is very similar to adenomyoepithelioma of the breast, which may be the same tumour at a different anatomical ... Seifert, G. (Sep 1998). "Are adenomyoepithelioma of the breast and epithelial-myoepithelial carcinoma of the salivary glands ...
Y. -X.; Shao, J. -Y. (2008). "MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage ... lymph node metastasis and patient poor prognosis". RNA. 14 (11): 2348-2360. doi:10.1261/rna.1034808. PMC 2578865 . PMID ... Guo, S. T.; Jiang, C. C.; Wang, G. P.; Li, Y. P.; Wang, C. Y.; Guo, X. Y.; Yang, R. H.; Feng, Y.; Wang, F. H.; Tseng, H. -Y.; ... Li, D.; Zhao, Y.; Liu, C.; Chen, X.; Qi, Y.; Jiang, Y.; Zou, C.; Zhang, X.; Liu, S.; Wang, X.; Zhao, D.; Sun, Q.; Zeng, Z.; ...
Y. -X.; Shao, J. -Y. (2008). "MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage ... lymph node metastasis and patient poor prognosis". RNA. 14 (11): 2348-2360. doi:10.1261/rna.1034808. PMC 2578865 . PMID ... Wang, X. Y.; Wu, M. H.; Liu, F.; Li, Y.; Li, N.; Li, G. Y.; Shen, S. R. (2010). "Differential miRNA expression and their target ... Duan, J.; Huang, H.; Lv, X.; Wang, H.; Tang, Z.; Sun, H.; Li, Q.; Ai, J.; Tan, R.; Liu, Y.; Chen, M.; Duan, W.; Wei, Y.; Zhou, ...
Therefore, ferroportin is a pivotal protein in breast biology and a strong and independent predictor of prognosis in breast ... Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full ... "Ferroportin and iron regulation in breast cancer progression and prognosis". Science Translational Medicine. 2 (43): 43ra56. ... Transfection of breast cancer cells with ferroportin significantly reduces their growth after orthotopic implantation in the ...
Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years ... The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain ... However, some cancers such as lymphomas, small cell lung carcinomas (SCLC) and breast cancer may be highly chemosensitive and ... The prognosis for brain metastases is variable. It depends on the type of primary cancer, the age of the patient, the absence ...
Woodfield GW, Horan AD, Chen Y, Weigel RJ (2007). "TFAP2C controls hormone response in breast cancer cells through multiple ... 2003). "Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis". Cancer. 98 (1 ... It also represses CD44 expression, which is a cell marker for some breast and prostate cancers. Mutations of this transcription ... Woodfield GW, Hitchler MJ, Chen Y, et al. (2009). "Interaction of TFAP2C with the estrogen receptor-alpha promoter is ...
McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H (Jan 2010). "Prognosis of hormone-dependent breast ... Muroya K, Hasegawa T, Ito Y, Nagai T, Isotani H, Iwata Y, Yamamoto K, Fujimoto S, Seishu S, Fukushima Y, Hasegawa Y, Ogata T ( ... "Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours". Breast ... Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer". Breast Cancer Research. 11 (2 ...
5-year survival rate. Breast implant-associated ALCL has an excellent prognosis when the lymphoma is confined to the fluid or ... Systemic ALK+ ALCL 5-year survival: 70-80%. Systemic ALK- ALCL 5-year survival: 15-45%. Primary Cutaneous ALCL: Prognosis is ... A rare subtype of ALCL has been identified in a few women who have silicone breast implants (protheses) as a result of breast ... A 2008 study found an increased risk of ALCL of the breast in women with silicone breast implants (protheses), although the ...
Sunn felt a lump in her breast which turned out to be breast cancer. When she was diagnosed in 1983, her prognosis was for one ... In August 1996 she was inducted into the Surfing Walk of Fame as that year's Woman of the Year; the Walk is in Huntington Beach ... Over the next 14 years, her cancer went into remission three times, and she underwent a mastectomy and a bone marrow transplant ... She helped pilot a program for breast cancer awareness at the Wai'anae Cancer Research Center that involved educating local ...
Fujiwara Y, Ochiya T (June 2015). "The expression and clinical significance of ribophorin II (RPN2) in human breast cancer". ... "RPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis". Molecular Therapy. Nucleic Acids. ... Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K, Ochiya T (February 2015). "Prognostic and therapeutic impact of RPN2- ... Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K, Baba H (October 2012). "RPN2 ...
... in breast tumors: a new potential biomarker for prognosis of breast carcinoma". Thromb Haemost. 91 (1): 180-186. doi:10.1267/ ... Vasilopoulos Y, Cork MJ, Murphy R, et al. (2004). "Genetic association between an AACC insertion in the 3'UTR of the stratum ... Dong Y, Kaushal A, Brattsand M, et al. (2004). "Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces ... Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, ...
Medical treatment of gynecomastia is most effective when done within the first two years after the start of male breast ... PrognosisEdit. Gynecomastia is not physically harmful, but in some cases it may be an indicator of other more serious ... Other causes of male breast enlargement such as mastitis,[14][36] breast cancer, pseudogynecomastia, lipoma, sebaceous cyst, ... Koshy, JC; Goldberg, JS; Wolfswinkel, EM; Ge, Y; Heller, L (January 2011). "Breast cancer incidence in adolescent males ...
In general women with this cancer have a very good prognosis, with mortality in 10 years of only 5%. Therefore, it is rare for ... B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast ... Zhou XY, Wang X, Hu B, Guan J, Iliakis G, Wang Y (March 2002). "An ATM-independent S-phase checkpoint response involves CHK1 ... Nigam N, Prasad S, George J, Shukla Y (April 2009). "Lupeol induces p53 and cyclin-B-mediated G2/M arrest and targets apoptosis ...
"E1AF expression levels are not associated with prognosis in human breast cancer". Breast Cancer Research and Treatment. 79 (1 ... Zhu X, Jiang J, Shen H, Wang H, Zong H, Li Z, Yang Y, Niu Z, Liu W, Chen X, Hu Y, Gu J (Apr 2005). "Elevated beta1,4- ... Suzuki Y, Yamashita R, Shirota M, Sakakibara Y, Chiba J, Mizushima-Sugano J, Nakai K, Sugano S (Sep 2004). "Sequence comparison ... Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, Imai K (May 2005). "Association of Ets-related ...
Younger women with an age of less than 40 years or women over 80 years tend to have a poorer prognosis than post-menopausal ... Mouse models of breast cancer metastasis. References[edit]. *^ a b c d e f g h i j k l m "Breast Cancer Treatment (PDQ®)". NCI ... Breast cancer is cancer that develops from breast tissue.[8] Signs of breast cancer may include a lump in the breast, a change ... Böhm I (2011). "Breast cancer in lupus". Breast. 20 (3): 288-90. doi:10.1016/j.breast.2010.12.005. PMID 21237645.. ...
... in therapy have improved the prognosis considerably and at least one third of women will survive the diagnosis by 10 years or ... Kusama, M; Koyanagi, Y; Sekine, M; Serizawa, H; Ebihara, Y; Hirota, T; Nakamura, Y; Matsunaga, T (1994). "A case of ... Inflammatory Breast Cancer Association. References[edit]. *^ "Inflammatory Breast Cancer: Questions and Answers". National ... Inflammatory breast cancer[1] is one of the most aggressive types of breast cancer that can occur in women of any age (and, ...
23-year-old Kristin Hallenga's health crusade to warn women about risks of breast cancer, Retrieved - June 8 2015 Change ... she has survived her original prognosis by living with terminal cancer for over five years. I was diagnosed in 2009, and I was ... Hallenga was diagnosed with breast cancer at the age of 23. Her doctor originally dismissed a tumor on Hallenga's breast as " ... I was told three times that I was too young to get breast cancer. I decided that my story needs to be told and we need to get ...
Dykxhoorn DM, Wu Y, Xie H, et al. (2009). Blagosklonny MV, ed. "miR-200 enhances mouse breast cancer cell colonization to form ... MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer ... Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009). "Up-regulation of miR-200 and let-7 by natural agents ... Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH (2009). "miR-200 regulates PDGF-D-mediated epithelial-mesenchymal ...
Yang XR, Xu Y, Yu B, et al. (2009). "CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery". ... 2009). "Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer". ... 2008). "The CD44+/CD24- phenotype is enriched in basal-like breast tumors". Breast Cancer Res. 10 (3): R53. doi:10.1186/bcr2108 ... Liu Y, Chen GY, Zheng P (2009). "CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns". Trends ...
Prognosis. 10 year shorter life expectancy[10]. Frequency. 392 million (2015)[11]. ... "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: ... Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF (July 2016). "Comparison ... Pan A, Wang Y, Talaei M, Hu FB, Wu T (December 2015). "Relation of active, passive, and quitting smoking with incident type 2 ...
Symptoms of fibrocystic breasts | AdaWhat are fibrocystic breasts? Ada doctors explain its signs, symptoms (lumpy, painful breasts), diagnosis, causes, and ... What is the prognosis for fibrocystic breasts?. Breast pain caused by fibrocystic mastopathy usually persists chronically for ... Good to know: The diagnostic value of a mammography can be limited, especially for women under 40 years of age, as the breast ... Change in breast size Local hardening which is palpable. If you think that you might have fibrocystic breasts, you can try ...
Mammography-Detected Breast Cancer In 40-49 Year-Olds Has Better Prognosis - RedorbitMammography-Detected Breast Cancer In 40-49 Year-Olds Has Better Prognosis. by editor ... Over the 18-year period, the number of breast cancers diagnosed at Stage 0 increased by 66 percent, while the number of Stage ... The data analysis revealed a significant increase in the percentage of mammography-detected breast cancer over the 18-year ... breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology. ...
RePub, Erasmus University Repository:
Long-term prognosis of young breast cancer patients (|= 40 years) who did not receive...Long-term prognosis of young breast cancer patients (,= 40 years) who did not receive adjuvant systemic treatment. Publication ... Long-term prognosis of young breast cancer patients (<= 40 years) who did not receive adjuvant systemic treatment. BMJ Open, 7( ... Our aim is to reduce overtreatment of women diagnosed with breast cancer aged ≤40 years.. Methods and analysis All young, ... breast tumours, epidemiology, histopathology Persistent URL. dx.doi.org/10.1136/bmjopen-2017-017842, hdl.handle.net/1765/105836 ...
The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast ... The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast ... Breast carcinoma, Breast conservation, Diagnosis, Local recurrence, Prognosis Persistent URL. dx.doi.org/10.1016/j.ejso.2005.10 ... Aims: The increasing use of breast-conserving therapy (BCT) and the rising incidence and improved prognosis of early breast are ...
Prognosis and adjuvant treatment effects in very young women (below 35 years) with operable breast cancer - fedOAPrognosis and adjuvant treatment effects in very young women (below 35 years) with operable breast cancer. ... Cancello, Giuseppe (2009) Prognosis and adjuvant treatment effects in very young women (below 35 years) with operable breast ... Conclusions: Very young patients with triple negative, luminal B, or HER2 positive breast cancer have a worse prognosis when ... Background: There is limited knowledge about prognosis of selected breast cancer subtypes among very young women Patients and ...
Better Prognosis For 40-49 Year-Olds Breast Cancer Patients Diagnosed Using Mammography. *Life Style ... Home Life Style Better Prognosis For 40-49 Year-Olds Breast Cancer Patients Diagnosed Using Mammography ... Better Prognosis For 40-49 Year-Olds Breast Cancer Patients Diagnosed Using Mammography. ... mammography-detected breast cancers between 40 and 49 years have a better prognosis and longer survival rates. ...
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience30 years appear to have a poorer prognosis compared with that for their older counterparts.,/p, ... p,Women who are diagnosed with breast carcinoma at an age , or = ... Female patients with breast carcinoma age 30 years and younger ... Conclusions: Women who are diagnosed with breast carcinoma at an age , or = 30 years appear to have a poorer prognosis compared ... Methods: One hundred eighty-five women age , or = 30 years in whom a diagnosis of invasive breast carcinoma was made between ...
Its not very common in younger women, but in this case a 17-year-old girl had to fight ovarian cancer. Krislyn Brown is here ... Mitt Romney treated for prostate cancer over the summer; prognosis is good. ... Breast cancer genetics revealed: 72 new mutations discovered in global study. * News ... Ovarian Cancer 17-Year-Olds Story of Survival. Posted 12:00 pm, September 13, 2012, by Nancy B. Allen, Updated at 11:10AM, ...
Breast cancer in 30-year-old or younger patients: clinicopathologic characteristics and prognosis | World Journal of Surgical...The aim was to describe the clinicopathological features and prognosis of 30-year-old or younger patients with breast cancer. ... We reviewed the records of 1,406 consecutive patients aged ≤50 years with first diagnosis of invasive breast cancer referred to ... A total of 105 patients were aged ≤30 years (group I) and 1,301 were aged 31-50 years (group II). Compared with patients of ... 30 years have a greater chance of having an endocrine-unresponsive tumor and a significantly poor prognosis. ...
Regional Differences in Breast Cancer Survival Despite Common Guidelines | Cancer Epidemiology, Biomarkers & PreventionOverall Prognosis. The unadjusted 7-year RSR was significantly lower in county A than in several of the other counties (Table 1 ... Cumulative 7-year survival ratio (RSR) of female breast cancer patients ages 40 to 69 years diagnosed between 1992 and 2002 ( ... women younger than 40 years old or older than 69 years old who are not recommended for the breast cancer screening program or ... ages 40 to 69 years diagnosed with primary breast cancer between 1992 and 2002 were followed up until 2003. The 7-year relative ...
Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell...Yang Y, Li Y, Wang K, Wang Y, Yin W, Li L. P38/NF-kappaB/snail pathway is involved in caffeic acid-induced inhibition of cancer ... and invasion of breast cancer cells and that low IDH1 expression correlates with poor prognosis in patients with breast cancer ... Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al. Glioma-derived mutations in IDH1 dominantly ... IDH1lowsnailhigh molecular signature is an independent marker for poor prognosis in breast cancer. Using the IHC data, we ...
... in peripheral blood could be a prognostic factor in breast cancer. We examined PLS3 expression in breast cancer cell lines with ... Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well ... Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis. ... We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical ...
BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC - ONADuring the two years following diagnosis, younger patients with BRCA-mutation positive, TNBC may have greater survival than non ... More in Breast Cancer. FDA: Number of U.S. Women With Breast Implant-Caused ... Textured breast implants linked to cases of ... BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC. Share this content: *facebook ... During the median follow-up of 8.2 years, 651 (96%) of 678 deaths were attributed to breast cancer. Further multivariable ...
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer | PNAS2001) Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant ... of all breast cancers (1). Compared with other breast cancer subtypes, TNBC is characterized by a worse prognosis and increased ... CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Sherene Loi, Sandra Pommey, ... TNBC remains a challenging disease with the poorest prognosis of all of the breast cancer subtypes. Importantly, there are ...
Breast Cancer - Causes, Risks, Symptoms, Diagnosis, Staging, Treatment, Prevention & PrognosisEarly detection and life style changes help in controlling breast cancer. ... Breast cancer is a cancer that affects the breasts or mammary glands. ... 16% of women between the age of 40-60 years have breast-related problems. Of these 40% complain of breast lumps ... What is the Prognosis for Breast Cancer?. Breast cancer prognosis in a patient is determined by several factors such as staging ...
Olivia Newton-Johns diagnosis of a breast cancer recurrence after 25 years is shocking, given how rare a relapse is after that ... Like the singer, I reached my five-year cancer anniversary, then my 10-year, and most recently the 15-year anniversary of that ... Treatment plans and prognosis. According to numerous news sources, Newton-John has decided to treat her recurrence with ... stretching over 25 years) of a breast cancer recurrence happening more than 20 years after the initial diagnosis. ...
Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health | CMAJManuel-y-Keenoy B. . Influence of body weight on the prognosis of breast cancer survivors; nutritional approach after diagnosis ... Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res Treat ... Adjuvant diet to improve hormonal and metabolic factors affecting breast cancer prognosis. Ann N Y Acad Sci 2006; 1089:110-8. ... Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J Natl Cancer Inst 2014;106: ...
What Are the Survival Rates for HER2-Positive Breast Cancer? | Reference.comBreast cancer patients with high levels of the human epidermal growth factor receptor 2 have a 77.1 percent five-year survival ... A: The prognosis for patients with liver cancer is generally poor, with an overall five-year survival rate of 15 percent for ... Breast cancer patients with high levels of the human epidermal growth factor receptor 2 have a 77.1 percent five-year survival ... improve the prognosis of HER2-positive breast cancer patients and lead to lengthy remissions that can last for over 15 years. ...
Breast Cancer PrognosisThe stage of the cancer thus at the beginning of therapy determines the outlook of a breast cancer patient. ... Prognosis of outlook of any cancer depends on several factors. Notable among these is how early the cancer is detected and ... If breast cancer comes back, it is usually within the first 2 years. Breast cancer can come back 10 or 20 years after initially ... Over years, with the development of medicines and surgical procedures for breast cancer treatment the outlook for breast cancer ...
In addition, whereas microvessel density in breast tumors correlated with poor clinical outcome in breast cancer (29), a high ... evidence accumulated over the past 25 years indicates that blood vessels with HEV characteristics develop in nonlymphoid ... and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer. Ludovic Martinet, Ignacio Garrido, Thomas Filleron, ... explain the prognosis value of HEVs in breast cancer. In addition, recruitment of naive and central memory T cells through the ...
Because the WHEL cohort consists of early-stage breast cancer survivors who were enrolled on average 2 years after diagnosis, ... Soy Food Consumption and Breast Cancer Prognosis. Bette J. Caan, Loki Natarajan, Barbara Parker, Ellen B. Gold, Cynthia Thomson ... Soy Food Consumption and Breast Cancer Prognosis. Bette J. Caan, Loki Natarajan, Barbara Parker, Ellen B. Gold, Cynthia Thomson ... Soy Food Consumption and Breast Cancer Prognosis. Bette J. Caan, Loki Natarajan, Barbara Parker, Ellen B. Gold, Cynthia Thomson ...
Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study:...Small breast cancers confer a better prognosis than large ones. However, survival in the context of a screening programme is ... Twenty five year.... *Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast ... Breast cancer occurrence. The 89 835 women were followed for incident breast cancers for up to 25 years from the date of ... Breast cancer survival. Overall, 1005 women died from breast cancer during the 25 year follow-up period (1.1%) including 351 of ...
Impact of Obesity on Clinicopathologic Characteristics and Disease Prognosis in Pre- and Postmenopausal Breast Cancer Patients:...L. Sun, Y. Zhu, Q. Qian, and L. Tang, "Body mass index and prognosis of breast cancer: an analysis by menstruation status when ... The association between breast cancer prognosis and obesity is not as strong as with obesity and risk of breast cancer. In this ... J. K. Park, H. A. Park, J. J. Park, and Y. G. Cho, "Obesity and screening compliance for breast and cervical cancer in Korean ... Gunnarsdóttir et al., "Effect of obesity on prognosis after early-stage breast cancer," Journal of Clinical Oncology, vol. 29, ...
Robin Roberts has MDS. What is that? - The Washington Post... to your cells that suggest a less-favorable prognosis. Roberts was treated for breast cancer five years ago; the treatment ... Tallman was unable to comment directly on Robertss case or her prognosis. But he says, "It is true that if you develop MDS ... Hes 26 years old but still sees a pediatrician: Why some young adults dont move on ... Tallman believes the condition, which affects an estimated 15,000 to 20,000 people per year in the United States, is more ...
May 2019 | Southlake Oncology... recommended that women who have no breast cancer symptoms should do a breast cancer screening and a mammogram every two years. ... Prognosis for Stage 4 Colon Cancer. May 28, 2019. Receiving a diagnosis for stage IV colon cancer can be devastating but it ... ACP Says Women Should Have Breast Screening Every 2 Years. May 22, 2019 ... They gave this recommendation based on some evidence gathered and it is directed to women between 50 and 74 years who may be ...
DiagnosisSymptomsSubtypesPoorerDiagnosisBetter prognosisPrognosticHER2TissueInvasive breast cancerTamoxifenClinicopathologic characteristics and prognosisProgression and poor prognosisLymph nodesLess favourable prognosisSignificantlyBiomarkersTNBCAdjuvantPatients with breast cancerRisk of breast cancer recurrenceDiagnosed with breast cancerMethodsMammogramDetected breast cancerRecurrence of breast cancerGenesPatient's prognosisTreatmentMetastatic breast cancerCohort of womenMastectomyWomenMolecularOutcomeSurgeryTriple-negatiAffect prognosisPredicts prognosisPatient prognosisEstrogen receptor-positiveCharacteristicsClinicalCancers diagnosedTumourOncology
- If you think that you might have fibrocystic breasts, you can try using the Ada app to find out more about your symptoms. (ada.com)
- The symptoms in women with fibrocystic breasts can vary from woman to woman. (ada.com)
- In addition, the symptoms are often symmetrical and occur in both breasts. (ada.com)
- Individual subtypes can increase the risk of breast cancer . (ada.com)
- or = 30 years appear to have a poorer prognosis compared with that for their older counterparts. (nih.gov)
- 5 - 7 Also, women who are overweight or obese at the time of diagnosis have a poorer prognosis. (cmaj.ca)
- Frail and elderly patient with poor helth often have poorer outcome and lowered capacity to withstand therapy for breast cancer and respond adequately to therapy. (news-medical.net)
- Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). (ebscohost.com)
- About 44 percent of women with "interval cancers" were deemed to have a poorer prognosis, compared to about 27 percent of women whose cancer had been spotted on their last regularly scheduled mammogram. (ahealthyme.com)
- TNBCs, accounting for about 11-20% of invasive breast cancers, are more aggressive, have a poorer prognosis, and have few targeted treatment options, compared with hormone-sensitive breast cancers. (labome.org)
- Compared to other types of breast cancer, TNBC is more aggressive and has a poorer prognosis. (utaustinportugal.org)
- It could be assumed that dense breast tissue would also be associated with a poorer prognosis in patients with a recently diagnosed breast cancer. (eurekalert.org)
- This means that younger women have a greater risk that their breast cancer will come back and a poorer overall prognosis than older, post-menopausal women. (cancer.ca)
- The shift toward more mammography-detected breast cancer cases was accompanied by a shift toward diagnosis at an earlier stage of disease that required less treatment," Dr. Malmgren said. (redorbit.com)
- Dr. Malmgren pointed out that changing modalities of diagnosis of breast cancer during the last 18 years and the introduction of mammography led to an earlier diagnosis. (doctortipster.com)
- We reviewed the records of 1,406 consecutive patients aged ≤50 years with first diagnosis of invasive breast cancer referred to surgery from March 2001 to March 2009. (biomedcentral.com)
- For the Prospective Outcomes in Sporadic vs Hereditary breast cancer (POSH) study, researchers evaluated the outcomes of 2733 younger women with first-diagnosis breast cancer, of whom 338 (12%) carried the BRCA germline mutation. (oncologynurseadvisor.com)
- most survivors suffer a recurrence within the first 10 years after diagnosis. (healthcentral.com)
- According to an article in the Journal of Clinical Oncology , reported in the online American College of Surgeons' ACS Surgery News, the chance of a breast cancer recurrence 25 years after initial diagnosis is .7 percent - i.e., just 7 of 1,000 survivors will experience such a relapse. (healthcentral.com)
- Like Newton-John, I was diagnosed with breast cancer in my 40s, an age when a breast cancer diagnosis can be quite dangerous. (healthcentral.com)
- Like the singer, I reached my five-year cancer anniversary, then my 10-year, and most recently the 15-year anniversary of that initial diagnosis. (healthcentral.com)
- After wryly answering "You can quit worrying when you die of something else," he reassured me that he'd seen only one case in his career (stretching over 25 years) of a breast cancer recurrence happening more than 20 years after the initial diagnosis. (healthcentral.com)
- Although more than 90% of patients with breast cancer have early stage disease at diagnosis, about 25% will eventually die of distant metastasis. (cmaj.ca)
- Overall, in the UK, more than 85% diagnosed with breast cancer live for at least 5 years after diagnosis. (news-medical.net)
- These studies, taken together, which vary in ethnic composition (two from the United States and one from China) and by level and type of soy consumption, provide the necessary epidemiologic evidence that clinicians no longer need to advise against soy consumption for women with a diagnosis of breast cancer. (aacrjournals.org)
- Briefly, 3,088 breast cancer survivors with a diagnosis between 1991 and 2000 who participated in a dietary intervention trial were followed throughout and after completion of the trial that ended in 2006. (aacrjournals.org)
- Enrolled participants had a diagnosis of and completed treatment (within the previous 4 years) of stage I, II, or III (AJCC VI classification) invasive breast cancer. (aacrjournals.org)
- During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer. (bmj.com)
- After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis. (bmj.com)
- Mean age at diagnosis was 50.98 ± 10.96 years. (hindawi.com)
- Obesity was associated with advanced stage and grade of breast carcinoma at diagnosis. (hindawi.com)
- Results: During a median of 6.7 years follow-up after diagnosis, n = 106 total deaths, n = 83 breast cancer-specific deaths, and n = 82 nonfatal recurrences were confirmed. (wur.nl)
- There's only a one-percent chance of anyone with this diagnosis would die of breast cancer. (people.com)
- Despite advances in the technologies used for its diagnosis and treatment, recurrence and metastasis of breast cancer remain serious clinical issues. (spandidos-publications.com)
- McCarthy said that "the rate of cancer diagnosis within one year of a negative mammogram was small -- 5.9 per 10,000 screenings -- but those cancers were more likely to have poor prognosis than cancers diagnosed after a positive mammogram. (ahealthyme.com)
- Storm Miller had been battling cancer for five years when she received a terminal diagnosis. (cbc.ca)
- In mid-April, test results came back with a shocking diagnosis - Hannah has Stage IIA Invasive Ductal Carcinoma, an adult form of breast cancer. (dailybulletin.com)
- The diagnosis means Hannah will likely have a mastectomy of her left breast, which will be reconstructed once she has developed. (dailybulletin.com)
- A growing body of literature suggests post- diagnosis, lifestyle-related factors may impact overall breast cancer prognosis. (labome.org)
- This effort has not been feasible in the past due primarily to the need for data on post- diagnosis lifestyle factors and breast cancer outcomes in a large population of women with TNBC. (labome.org)
- Seizures are a presenting symptom in approximately 20% of patients with supratentorial brain tumors and may antedate the clinical diagnosis by months to years in patients with slow-growing tumors. (oncolink.org)
- Guangdong Provincial Science and Technology Planning Project (2011B031800305/ http://www.gdstc.gov.cn/eng/mission.html ) and Guangdong Provincial Key Laboratory on Breast Cancer Diagnosis and Treatment Research. (plos.org)
- Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. (medworm.com)
- Although most diagnosis of breast pathology is accomplished using hematoxylin and eosin stained sections, some cases require immunohistochemistry for proper evaluation. (medworm.com)
- Breast tissue density was analysed on the basis of mammographic images obtained at the time of diagnosis. (eurekalert.org)
- The diagnosis of breast cancer is confirmed by taking a biopsy of the concerning lump. (wikipedia.org)
- Once the diagnosis is made, further tests are done to determine if the cancer has spread beyond the breast and which treatments it may respond to. (wikipedia.org)
- This is partially related to the often late diagnosis of male breast cancer , when the cancer has already spread. (medicinenet.com)
- Their breast cancer is often more advanced at the time of diagnosis. (cancer.ca)
- Women whose breast cancer comes back more than 5 years after their diagnosis usually have a better outcome than those who have a recurrence less than 2 years after diagnosis. (cancer.ca)
- Flagging in the national Medical Research Information Service database means that the patients taking part in the study can be tracked for twenty years following diagnosis. (southampton.ac.uk)
- In addition, linking in with researchers in qualitative medicine in the Faculty of Health Sciences, a Research for Patient Benefit project (funded by the NIHR) will use the POSH patient cohort and experience of the diagnosis and treatment of breast cancer in this age group to explore and improve approaches to information giving at diagnosis. (southampton.ac.uk)
- Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. (redorbit.com)
- Dr. Malmgren emphasised the crucial role of mammography and concluded that its main objective is to detect breast cancer in its earlier stages and therefore contributing a better prognosis and chances of complete remission. (doctortipster.com)
- Small breast cancers confer a better prognosis than large ones. (bmj.com)
- Patients expressing high levels of ATBF1-A mRNA tended to have a better prognosis than those expressing low levels. (aacrjournals.org)
- Low-grade tumours have a better prognosis because they grow slower and are less likely to spread than high-grade tumours. (cancer.ca)
- Differences in gene expression found between patients with a favourable and those with a less favourable prognosis will be used to establish a prognostic classifier, using the triple negative patients as proof of principle. (eur.nl)
- Therefore, investigating the detailed mechanisms of breast cancer metastasis or developing a favorable prognostic biomarker to predict prognostic outcomes in patients with breast cancer is beneficial. (springer.com)
- In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 ( PLS3 ) in peripheral blood could be a prognostic factor in breast cancer. (nature.com)
- The Nottingham Prognostic Index (NPI) that determines outcome or prognosis of breast cancer is based on grade of the cancer. (news-medical.net)
- To investigate the association between obesity and breast cancer clinicopathologic characteristics at presentation along with prognostic impact among Jordanian breast cancer patients. (hindawi.com)
- Over the past 15 years, gene expression studies in breast cancer have led to more accurate prognostic tools and to a greater understanding of the molecular heterogeneity of breast cancer. (nature.com)
- Agendia was the first company to commercialize a prognostic test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. (bio-medicine.org)
- The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. (diva-portal.org)
- An association between lack of IGF1R expression and worse prognosis was mainly seen in the ER-negative part of Cohort I. The lack of co-activation of downstream markers (p-mTOR and p-S6rp) in the IGF1R pathway suggested that the prognostic effect was not due to complete activation of this pathway. (diva-portal.org)
- Conclusions CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity, and CA9 expression in resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and weekly paclitaxel prior to resection. (ebscohost.com)
- Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. (ebscohost.com)
- It was conducted on 267 metastatic breast cancer patients treated by first line chemotherapy, which confirmed that CTC levels are an independent prognostic. (ebscohost.com)
- Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. (ebscohost.com)
- The traditional prognostic and predictive factors in breast cancer mainly focus on the clinical-pathological parameters, which are unable to reveal the diverse molecular alterations of breast cancer and are imprecise in predicting breast cancer progression and clinical outcomes. (springer.com)
- Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. (springer.com)
- Our results demonstrate that Twist expression is an important prognostic factor in breast cancer patients. (plos.org)
- Pathological prognostic factors in breast cancer. (medigraphic.com)
- Prognostic Factors in Breast Cancer. (medigraphic.com)
- A comparative study of two histological prognostic features in operable breast carcinoma. (medigraphic.com)
- Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. (medigraphic.com)
- Otsuki Y, Shimizu S, Suwa K, Yoshida M, Kanzaki M, Kobayashi H. Which is Better Pathological Prognostic Factor, the Nottingham Histological Grade or the Japanese Nuclear Grade? (medigraphic.com)
- The results indicate that a very low breast tissue density is an independent poor prognostic factor of breast cancer, regardless of patients' age, menopausal status or body mass index. (eurekalert.org)
- In addition, multivariate analysis indicated that KIF2A was an independent prognostic for outcome in breast cancer (OR: 16.55, 95% CI: 2.216-123.631, P = 0.006). (whiterose.ac.uk)
- KIF2A may play an important role in breast cancer progression and is potentially a novel predictive and prognostic marker for breast cancer. (whiterose.ac.uk)
- The combination of grade, tumour size and lymph node status in the Nottingham Prognostic Index provides a powerful instrument separating patients in groups with excellent, good, intermediate and poor prognosis. (diva-portal.org)
- The results of this study also imply that ATBF1-A gene expression may have potential both as a marker of endocrine responsiveness and also as a prognostic indicator for breast cancer progression. (aacrjournals.org)
- In 1982 we constructed a prognostic index for patients with primary, operable breast cancer. (nih.gov)
- We now present the results of applying this prognostic index to all of the first 1,629 patients in our series of operable breast cancer up to the age of 70. (nih.gov)
- A prognostic factor is an aspect of the cancer or a characteristic of the person that the doctor will consider when making a prognosis. (cancer.ca)
- Doctors use different prognostic and predictive factors for newly diagnosed and recurrent breast cancers. (cancer.ca)
- The following are prognostic and predictive factors for breast cancer when it is first found and diagnosed. (cancer.ca)
- The stage is the main prognostic factor for breast cancer. (cancer.ca)
- Whether or not cancer has spread to lymph nodes is the most important prognostic factor for breast cancer. (cancer.ca)
- The size of the tumour is the 2nd most important prognostic factor for breast cancer. (cancer.ca)
- 2019). Male breast cancer in the United States: Treatment patterns and prognostic factors in the twenty-rst Century. (news-medical.net)
- The findings suggest that when genomic profile information is available for a given patient in the clinic, this machine learning-assisted risk scoring approach could have prognostic value, she said, noting that the model also will be assessed in patients with other types of breast cancer. (mdedge.com)
- Exploring the validity of available prognostic predictors in younger women with breast cancer as a project within the MSc Clinical Trials and Statistics course in Southampton. (southampton.ac.uk)
- HR 2.20, 95%CI, 1.10-4.41, for OS) breast cancer, observing the highest risk of recurrence in the younger patients with HER2 positive breast cancer (HR 2.37, 95% CI, 1.12-5.02), when compared with older patients. (unina.it)
- Conclusions: Very young patients with triple negative, luminal B, or HER2 positive breast cancer have a worse prognosis when compared with older patients with similar characteristics of disease. (unina.it)
- Triple-negative breast cancer (TNBC), as defined by the absence of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression, accounts for 15-20% of all breast cancers ( 1 ). (pnas.org)
- Herceptin is arguably the most effective treatment for HER2-positive breast cancer. (medindia.net)
- Up to 70 percent of patients with metastatic HER2-positive breast cancer respond to treatment, but only 7 to 8 percent of patients experience complete remission, explains the New England Journal of Medicine. (reference.com)
- Treatments, such as trastuzumab, which target the HER2 protein improve the prognosis of HER2-positive breast cancer patients and lead to lengthy remissions that can last for over 15 years. (reference.com)
- HER2-positive cancer usually occurs in younger women and is more quickly-growing and aggressive than other types of breast cancer. (news-medical.net)
- The HER2 marker is present in about 20% of cases of invasive breast cancer. (news-medical.net)
- The remaining breast cancers are classified into HER2 positive or triple negative breast cancer. (diva-portal.org)
- It is considered tissue-protective in luminal breast cancer, while it's role in HER2 positive and triple negative breast cancers is less defined, but is generally considered to be associated with worse outcome. (diva-portal.org)
- Triple-negative breast cancer is any cancer that tests negative for three of the main things -- the hormones estrogen and progesterone and a protein called HER2 -- that drive other forms of the disease. (webmd.com)
- That means there aren't targeted therapies approved to treat it like there are for other types, like HER2 -positive breast cancer. (webmd.com)
- If your cells don't test positive for estrogen , progesterone, or HER2 receptors, then it's diagnosed as triple-negative breast cancer. (webmd.com)
- DESCRIPTION (provided by applicant): Triple negative breast cancers (TNBCs) are defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) negative. (labome.org)
- Targeted therapy is not available for TNBC because this subtype of breast cancer lacks the expression of ER, PR and HER2. (utaustinportugal.org)
- estudio transversal, anal tico, efectuado en 884 mujeres con diagn stico de c ncer de mama de las que se estudiaron 768 con tumores de tipo histol gico de carcinoma ductal infiltrante, en 596 (77.60%) se definieron cinco perfiles de expresi n inmunohistoqu mica (luminal A, luminal B, mixto, HER2/ neu y triple negativo). (medigraphic.com)
- de 596 casos, 201 (33.72%) fueron: luminal A, 40 (6.71%) luminal B, 77 (12.91%) mixto, 108 (18.12%) HER2/neu y 170 (28.52%) triple negativo. (medigraphic.com)
- El an lisis multivariado encontr asociaci n para mayor riesgo de muerte en subtipos HER2/neu positivo (LR= 7.193, p = 0.007) y mixto (LR= 5.191, p = 0.023), y la radioterapia se revel como factor protector (LR= 0.678, p = 0.001). (medigraphic.com)
- A breast cancer is HER2-positive when it has much higher levels of the protein than normal. (mdanderson.org)
- HER2-positive breast cancer means that the cancer cells make too many copies of, or overexpress, the HER2 gene. (cancer.ca)
- HER2-positive breast cancer is more aggressive and more likely to spread than HER2-negative breast cancer. (cancer.ca)
- This means that HER2-positive breast cancer has a less favourable prognosis than HER2-negative breast cancer. (cancer.ca)
- Breast cancer cells may or may not have many different types of receptors, the three most important in the present classification being: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. (wikipedia.org)
- Tissue slides will be digitalised and placed on an online image database platform for clinicopathological revision by an international team of breast pathologists. (eur.nl)
- Breast cancer can recur locally in breast or scar tissue, or distantly in other parts of the body including bones or organs. (healthline.com)
- αB-crystallin protein expression was determined by immunohistochemistry using the clinically annotated British Columbia Cancer Agency (BCCA) tissue microarray ( n =3,987 breast tumors). (nature.com)
- The healthy breast is a tissue composed of centrally located milk producing glands connected to the nipple by ducts, surrounded by fat tissue and connective tissue. (diva-portal.org)
- The growth of the breast is primarily mediated by the estrogens, while the androgens mediate tissue homeostasis and protect against growth signals. (diva-portal.org)
- She was diagnosed with a non-invasive form of breast cancer called ductal carcinoma in situ, or DCIS, which in her case was confined to the milk ducts and had not spread to the breast tissue. (people.com)
- When doctors find an area in your breast that isn't normal, they'll cut out a little bit of the tissue to test the cells. (webmd.com)
- The density of breast tissue also seemed to matter -- the study found that women with denser breasts were at a higher risk of having an interval cancer. (ahealthyme.com)
- However, having denser breast tissue "did not predict whether that cancer would have poor prognosis," McCarthy noted. (ahealthyme.com)
- Adding sonograms to women with dense breast tissue is one way to try to capture some of the cancers missed on mammogram while they are smaller and have not yet spread to the lymph nodes under the arm," Bernik said. (ahealthyme.com)
- [ 11 ] Second, by placing most retained breast tissue at or above the inframammary fold, a favorable change in weight vectors on the upper thorax and spine is produced. (medscape.com)
- Medial and lateral skin excision limits are identified by lateral and medial displacement of breast tissue using the native breast meridian as the reference line. (medscape.com)
- Breast augmentation is done by placing implants behind breast tissue or under the chest muscle. (medlineplus.gov)
- It is normal for your body to create a "capsule" made up of scar tissue around your new breast implant. (medlineplus.gov)
- This may cause a change in the shape of your breast, hardening of breast tissue, or some pain. (medlineplus.gov)
- For a breast reduction, the surgeon removes some of the breast tissue and skin. (medlineplus.gov)
- Extra fat, skin, and breast tissue are removed. (medlineplus.gov)
- Disease free survivals as well as overall life expectancies were significantly shorter in women with very low-density breasts in comparison to women with high density breast tissue. (eurekalert.org)
- The lower the breast tissue density, the less fibroglandular tissue there is compared to fat tissue. (eurekalert.org)
- The researchers determined the proportion of dense glandular tissue of the overall breast area. (eurekalert.org)
- The study was a six-year follow up focusing on the effects of breast tissue density and other mammographic features on breast cancer prognosis. (eurekalert.org)
- Out of the women with very low breast tissue density, 70.7% were alive at the end of the six-year follow-up, whereas out of women whose proportion of glandular tissue was higher than 10%, 87.7% were alive at the same time. (eurekalert.org)
- Lower breast tissue density was also associated with more aggressive higher grade tumours. (eurekalert.org)
- The results are particularly interesting because dense breast tissue has long been known to be associated with an increased risk of cancer. (eurekalert.org)
- In the U.S., it is nowadays mandatory to let patients know if they have dense breast tissue. (eurekalert.org)
- However, this was not the case in our study, as low breast tissue density specifically weakened the prognosis. (eurekalert.org)
- Breast cancer is cancer that develops from breast tissue. (wikipedia.org)
- The first noticeable symptom of breast cancer is typically a lump that feels different from the rest of the breast tissue. (wikipedia.org)
- Indications of breast cancer other than a lump may include thickening different from the other breast tissue, one breast becoming larger or lower, a nipple changing position or shape or becoming inverted, skin puckering or dimpling, a rash on or around a nipple, discharge from nipple/s, constant pain in part of the breast or armpit, and swelling beneath the armpit or around the collarbone. (wikipedia.org)
- The breast tissue can arise anywhere along the milk line (axilla to vulva). (brainscape.com)
- What hormone receptors are present in breast tissue? (brainscape.com)
- Where is the highest density of breast tissue located? (brainscape.com)
- Breast tissue: Women with dense breast tissue (as documented by mammogram ) have a higher risk of breast cancer. (medicinenet.com)
- Symptoms are similar to the symptoms in women, with the most common symptom being a lump or change in skin of the breast tissue or nipple discharge . (medicinenet.com)
- Men have breast tissue and they can also develop breast cancer. (news-medical.net)
- Grading focuses on the appearance of the breast cancer cells compared to the appearance of normal breast tissue. (wikipedia.org)
- Methods: In the period 1982-1997, 3280 patients with invasive breast cancer underwent breast-conserving therapy in one of the eight community hospitals in the South-eastern part of The Netherlands. (eur.nl)
- The retrospective study was conducted with a cohort of 146 unselected, primary, nonmetastatic, invasive breast cancer patients operated at the ICR between 1997 and 1998. (aacrjournals.org)
- A total of 107 consecutive young patients with invasive breast cancer undergoing surgery during 1980-1993 in the Southeast Swedish health care region were retrospectively followed up and their cancers reviewed and graded blindly. (diva-portal.org)
- According to Breastcancer.org , over 200,000 women will be diagnosed with new cases of invasive breast cancer in 2014. (miaminewtimes.com)
- ref. 7 ) and 1 in U.S. women from the Life After Cancer Epidemiology (LACE) study ( 8 ), suggest that soy-containing foods do not adversely affect breast cancer prognosis, do not counteract the benefits of tamoxifen and may, in fact, offer some potential benefits in decreasing risk of recurrence or death from breast cancer. (aacrjournals.org)
- In 2000, while still taking tamoxifen, the cancer recurred in the other breast. (healthline.com)
- Klein said until the past few years, the standard prescription was five years of tamoxifen or an aromatase inhibitor (AI). (healthline.com)
- In younger women with more aggressive disease, we always give 10 years of tamoxifen. (healthline.com)
- Treatment is also subtype specific, and luminal breast cancers in premenopausalwomen are treated using the estrogen receptor blocker (antagonist) tamoxifen, which blocks estrogen signaling. (diva-portal.org)
- In postmenopausal women, luminal breast cancers are treated using tamoxifen or aromatase inhibitors, which prevent the formation of estrogen. (diva-portal.org)
- One of the primary goals of this thesis was to establish biomarkers for prognosis and tamoxifen treatment in breast cancer, and paper I, paper II and paper III address this aim. (diva-portal.org)
- Cohort I (N = 264) consisted of mainly postmenopausal women with stage II breast cancer treated with tamoxifen for 2 years irrespective of ER status. (diva-portal.org)
- Results: We found that lower IGF1R expression was associated with worse prognosis for tamoxifen treated, postmenopausal women (HR = 0.70, 95% CI = 0.52 - 0.94, p = 0.016). (diva-portal.org)
- The medications tamoxifen or raloxifene may be used in an effort to prevent breast cancer in those who are at high risk of developing it. (wikipedia.org)
- In terms of medications used to treat male breast cancer, they found that the most common drug used was Tamoxifen, which is an anti-estrogen medication. (news-medical.net)
- How long do I need to take tamoxifen for breast cancer? (netdoctor.co.uk)
- Most women take tamoxifen for five to ten years. (netdoctor.co.uk)
- If you don't keep taking tamoxifen for the recommended amount of time this could worsen your prognosis. (netdoctor.co.uk)
- Some women who have passed the menopause may take tamoxifen for two, three or five years and then switch to a different medicine, called an aromatase inhibitor, such as anastrazole or exemestane . (netdoctor.co.uk)
- If you're taking tamoxifen for breast cancer that has come back you'll usually continue to take it for as long as it is keeping the cancer under control. (netdoctor.co.uk)
- The impact of BMI on clinicopathologic characteristics and prognosis was confined to postmenopausal cases. (hindawi.com)
- The perturbed expression was associated with disease progression and poor prognosis. (wikipedia.org)
- Has it spread to lymph nodes (glands near the breast) or other areas? (webmd.com)
- Poor prognosis" was defined as cancer that had already spread to lymph nodes or other body sites, or certain breast cancer subtypes that had already exceeded a certain size. (ahealthyme.com)
- Breast cancer can spread through nearby lymph nodes. (mdanderson.org)
- When young women are diagnosed with breast cancer their tumours are larger, their lymph nodes more often involved, and the median grade higher than in older with 64% having grade 3 tumours. (diva-portal.org)
- Women under 37 years of age had increased tumour size, more metastatic lymph nodes and doubled rate of high grade tumours as compared to older women. (diva-portal.org)
- Lumps found in lymph nodes located in the armpits can also indicate breast cancer. (wikipedia.org)
- The trial comprised 1,780 patients whose breast cancer had not spread to their lymph nodes. (medicalnewstoday.com)
- Doctors will consider if cancer has spread to lymph nodes and the size of the tumour when they predict a prognosis. (cancer.ca)
- Breast cancer that has spread to lymph nodes has a higher risk of coming back and a less favourable prognosis than breast cancer that has not spread to the lymph nodes. (cancer.ca)
- The more positive lymph nodes there are, the higher the risk that breast cancer will come back. (cancer.ca)
- Breast cancer that has spread to 4 or more lymph nodes has the highest risk for recurrence. (cancer.ca)
- The tumour size will affect prognosis no matter how many lymph nodes have cancer in them. (cancer.ca)
- Breast tumours that are smaller than 1 cm and have not spread to the lymph nodes have a very favourable prognosis. (cancer.ca)
- Stages 1-3 are within the breast or regional lymph nodes. (wikipedia.org)
- Breast cancer diagnosed at a later stage has a greater risk of recurrence, so it has a less favourable prognosis. (cancer.ca)
- Conclusion: The prognosis of patients with a local recurrence more than 5 years after BCT is significantly better than of patients with local recurrence within 5 years after BCT. (eur.nl)
- Results: Patients below 35 years of age (315, 11%) presented a significantly increased risk of recurrence and death (HR=1.65, 95%CI 1.30-2.10 and HR=1.78, 95%CI 1.12-2.85, respectively) when compared with older patients (2655, 89%) with similar characteristics of disease. (unina.it)
- The present findings revealed that the mRNA and protein expression levels of IDH1 were both significantly lower in breast cancer tissues than in adjacent normal tissues. (springer.com)
- The number of women dying from breast cancer has gone down significantly in the last 20 years in the UK mainly because of efficient and early screening and detection of the cancer. (news-medical.net)
- In the last 20 years, advances in radiotherapy have significantly improved the prognosis for brain cancer patients. (scienceblogs.com)
- Breast cancer mortality trends have declined significantly during the past decade, largely due to public awareness campaigns that focus on early detection and prevention. (medicalnewstoday.com)
- Studies have shown people who exercise for a total of four hours each week have a significantly lower risk of developing breast cancer. (cancertutor.com)
- Inheriting a mutated gene from a parent means that one has a significantly higher risk of developing breast cancer. (medicinenet.com)
- Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. (nature.com)
- Biomarkers in cancer staging, prognosis, and treatment selection. (springer.com)
- Overexpression of Twist led to dramatic changes in cellular morphology, proliferation, migratory/invasive capability, and expression of EMT-related biomarkers in breast cancer cells. (plos.org)
- Study participants with TNBC and BRCA-mutations had an improved 2-year OS rate compared to noncarriers. (oncologynurseadvisor.com)
- Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is associated with a poor prognosis in triple-negative breast cancers (TNBC). (pnas.org)
- One of these sub-types is known as triple negative breast cancer (TNBC). (healthline.com)
- TNBC characteristically has a high recurrence rate, which drops down sharply after five years. (healthline.com)
- The risk of recurrence for TNBC is greatest within the first three years and declines rapidly after five years. (healthline.com)
- Once the five years are over, TNBC cancer rarely relapses, and a person can feel confident that they've been victorious over their cancer. (healthline.com)
- However, little is known about the role of modifiable lifestyle-related factors in TNBC prognosis. (labome.org)
- To date, no prospective cohort study has investigated lifestyle-related factors that have been implicated in breast cancer prognosis overall, specifically in the prognosis of TNBC. (labome.org)
- Our overall hypothesis is that the associations of lifestyle-related factors with breast cancer recurrence and mortality may differ for women with TNBC, as compared to women with ER+ breast cancer, depending on the underlying biological mechanisms for each lifestyle factor-breast cancer outcome association. (labome.org)
- The proposed collaborative study, which will pool the resources of six prospective cohorts of breast cancer survivors, will be the first study that is sufficiently powered to investigate the effect of modifible lifestyle-related factors on TNBC prognosis. (labome.org)
- The findings of our study will lead to public health recommendations and guidelines appropriate for breast cancer survivors with TNBC, information critically needed, with the ultimate goal of reducing morbidity and mortality among breast cancer survivors. (labome.org)
- Triple-negative breast cancer (TNBC) represents 20% of the 3 million new cases of breast cancer diagnosed in women worldwide every year. (utaustinportugal.org)
- Furthermore, TNBC often is among the highest-grade breast cancers. (utaustinportugal.org)
- Since breast cancers diagnosed at a young age are considered prognostically unfavourable, many treatment guidelines recommend adjuvant systemic treatment for all young patients. (eur.nl)
- Methods and analysis All young, adjuvant systemic treatment naive breast cancer patients, who had no prior malignancy and were diagnosed between 1989 and 2000, were identified using the population based Netherlands Cancer Registry (n=3525). (eur.nl)
- Conclusion Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. (bmj.com)
- Other types of adjuvant therapy, like hormone treatments, won't work with triple-negative breast cancer. (webmd.com)
- Omission of Histologic Grading From Clinical Decision Making May Result in Overuse of Adjuvant Therapies in Breast Cancer: Results From a Nationwide Study. (medigraphic.com)
- Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up. (medsci.org)
- Lack of prognosticators for young breast cancer patients represents an unmet medical need and has led to the initiation of the PAtients with bReAst cancer DIaGnosed preMenopausally (PARADIGM) initiative. (eur.nl)
- Dr. Malmgren along with a team researchers have conducted a study and reviewed the charts of patients with breast cancer aged between 40 and 49 years, treated between 1990 to 2008. (doctortipster.com)
- The number of 30-year-old or younger patients with breast cancer is increasing. (biomedcentral.com)
- The aim was to describe the clinicopathological features and prognosis of 30-year-old or younger patients with breast cancer. (biomedcentral.com)
- p = 0.002) in patients with breast cancer. (springer.com)
- We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression. (nature.com)
- In both the training ( n =298) and validation ( n =296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. (nature.com)
- These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. (nature.com)
- Herceptin, an aggressive anti-breast cancer therapy drug is well known to cause heart problems in patients with breast cancer. (medindia.net)
- 1 Many patients with breast cancer seek information from a variety of sources about behaviours that may reduce their risk of recurrence. (cmaj.ca)
- We review the role of lifestyle factors, particularly weight management, exercise, diet, smoking, alcohol intake and vitamin supplementation, on the prognosis of patients with breast cancer. (cmaj.ca)
- Most patients with breast cancer gain weight both during and after active treatment, and much of the weight is never lost. (cmaj.ca)
- Several modifiable lifestyle factors can influence the risk of development and the outcome of patients with breast cancer [ 6 ]. (hindawi.com)
- I have learned a tremendous amount over the years from my patients with breast cancer, especially those living with MBC. (swedish.org)
- New research shows that long-term endocrine therapy can reduce the risk of breast cancer recurrence in the long term. (healthline.com)
- For the new research, Dr. Esserman and colleagues decided to use this test to evaluate the risk of breast cancer recurrence over a period of 20 years after being diagnosed. (medicalnewstoday.com)
- Our aim is to reduce overtreatment of women diagnosed with breast cancer aged ≤40 years. (eur.nl)
- For over two decades Newton-John has been a tireless campaigner in support of other women diagnosed with breast cancer. (healthcentral.com)
- The numbers below come from the National Cancer Data Base, and are based on people who were diagnosed with breast cancer in 2001 and 2002. (news-medical.net)
- According to John's Hopkins Breast Center , about 10 to 20 percent of those diagnosed with breast cancer have the triple negative subtype. (healthline.com)
- Breast cancer is the most common malignancy in women, and it is estimated that 10% of all women will be diagnosed with breast cancer during their life-time. (diva-portal.org)
- Tennis legend Martina Navratilova has been diagnosed with breast cancer. (people.com)
- Hannah Powell-Auslam, 10, who has recently been diagnosed with breast cancer, adjusts her pink wrist band during her softball game at Behringer Park in La Mirada on Saturday April 25, 2009. (dailybulletin.com)
- Age-adjusted incidence and death rate for the 5394 Swedish women diagnosed with breast cancer under the age of 40 between 1960 and 1996 was studied using data from the Swedish Cancer Registry and Swedish Death Cause Registry. (diva-portal.org)
- World-wide about 794,000 women are diagnosed with breast cancer each year. (cancerindex.org)
- Women 70 and older are those most likely diagnosed with breast cancer. (cancertutor.com)
- Fewer than 5 percent of women diagnosed with breast cancer in the United States are younger than 40. (cancertutor.com)
- Personal history: Having been diagnosed with breast cancer in one breast increases the risk of cancer in the other breast or the chance of an additional cancer in the original breast. (medicinenet.com)
- This National Cancer Research Network Portfolio study has recruited over 3000 women diagnosed with breast cancer at very young ages (before 41 years. (southampton.ac.uk)
- That means about one in every eight women will be diagnosed with breast cancer. (miaminewtimes.com)
- My best friend, a healthy, young professional and the mother of a young boy, was recently diagnosed with breast cancer. (miaminewtimes.com)
- Methods: We conducted a population-based observational study using a clinical breast cancer register in one Swedish health care region. (aacrjournals.org)
- Methods: We investigated associations of dietary fiber, carbohydrates, GI, and GL with breast cancer prognosis among n = 688 stage 0 to IIIA breast cancer survivors in the Health, Eating, Activity, and Lifestyle (HEAL) study. (wur.nl)
- Methods A total of 102 patients with resectable early-stage breast cancer were treated with NAC consisting of FEC (5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. (ebscohost.com)
- Mammogram detected non-palpable breast cancers are smaller on average than clinically palpable breast cancers. (bmj.com)
- The American College of Physicians (ACP) has recommended that women who have no breast cancer symptoms should do a breast cancer screening and a mammogram every two years. (southlakeoncology.com)
- I cried," Navratilova, 53, tells PEOPLE about the moment in February when a biopsy came back positive after a routine mammogram revealed a cluster in her left breast. (people.com)
- THURSDAY, May 3, 2018 (HealthDay News) -- About 15 percent of breast cancers are diagnosed in the interval between regularly scheduled mammograms, where the last mammogram showed no signs of a cancer. (ahealthyme.com)
- Ask your surgeon if you need a screening mammogram based on your age and risk of having breast cancer. (medlineplus.gov)
- If I had postponed the mammogram for another year, my Stage 2 breast cancer undoubtedly would have progressed to a more advanced stage that could have been life-threatening. (courant.com)
- My prognosis is excellent thanks to early detection by an annual mammogram. (courant.com)
- The earliest breast cancers are detected by a mammogram . (wikipedia.org)
- Our goal was to assess the differences between mammography and non-mammography detected breast cancer, to determine whether earlier detection confers a treatment and morbidity advantage because the disease is found at an earlier stage," Dr. Malmgren said. (redorbit.com)
- The data analysis revealed a significant increase in the percentage of mammography-detected breast cancer over the 18-year period: from 28 percent in 1990 to 58 percent in 2008. (redorbit.com)
- Over the same period, patient- and physician-detected breast cancer declined from 73 percent of all cases in 1990 to 42 percent in 2008. (redorbit.com)
- Four-time Grammy winner Olivia Newton-John, an internationally renowned singer, songwriter, and actress (Grease), has been diagnosed with a recurrence of breast cancer . (healthcentral.com)
- Today I am cancer-free and am undergoing radiation treatments to prevent a recurrence of breast cancer. (courant.com)
- In familial breast cancers, a mutation in the genes BRCA1 and BRCA2 play a major role in the disease onset. (medindia.net)
- Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) of miR‑29b and certain target genes of miR‑29b, such as DNA methyltransferase 3A (DNMT3A), ten‑eleven translocation 1 (TET1) and thymine DNA glycosylase (TDG), was performed in 94 primary breast cancer samples. (spandidos-publications.com)
- The present study evaluated the importance of miR-29b in breast cancer cases and additionally showed the associations between miR-29b and several target genes of miR-29b indicated in the regulation of DNA methylation status in clinical samples. (spandidos-publications.com)
- Polymorphisms in the KDR and POSTN genes : association with breast cancer susceptibility and prognosis. (diva-portal.org)
- Genetic risk factors: The most common causes are mutations in the BRCA1 and BRCA2 genes (breast cancer and ovarian cancer genes). (medicinenet.com)
- Introduction Currently used tools for breast cancer prognostication and prediction may not adequately reflect a young patient's prognosis or likely treatment benefit because they were not adequately validated in young patients. (eur.nl)
- The benefits of breast cancer treatment are accompanied by significant harms," Dr. Malmgren said. (redorbit.com)
- He noted that in mammography diagnosed breast cancer, patients underwent a conservative treatment. (doctortipster.com)
- 30 years and who were identified in the same data base and received treatment during the same period served as the control population. (nih.gov)
- In addition, data on treatment effects are largely dependent upon older series collected over several years and extrapolation of data from older age cohorts. (biomedcentral.com)
- Within regions, treatment by clinicians with specialist training, a longer practice, or a greater case load and treatment at larger hospitals or units with a larger annual case load consistently improves quality of care for breast cancer ( 1 ). (aacrjournals.org)
- Women who gain weight during or after treatment of breast cancer have been consistently shown to be at higher risk of breast cancer-related death. (cmaj.ca)
- Over years, with the development of medicines and surgical procedures for breast cancer treatment the outlook for breast cancer has continued to improve. (news-medical.net)
- Tallman says the condition can linger for years in some patients without needing treatment, while other patients will need therapy right away. (washingtonpost.com)
- Estrogen receptor-negative (ER(-)) breast cancers have limited treatment options and are associated with earlier relapses. (semanticscholar.org)
- As initially proposed, participants will undergo ultrasonography at baseline and every 6 months throughout the 2 to 5 years (average 3 years) of randomized treatment. (clinicaltrials.gov)
- Participants will also undergo cognitive testing at baseline and after 3 years of randomized treatment. (clinicaltrials.gov)
- The trial has been extended for an additional 2 to 2.5 years of randomized treatment (overall average randomized treatment of 5 years and range of 2 to 8.5 years). (clinicaltrials.gov)
- Women with early-stage, slow-growing ER+ cancers are often in treatment for 10 years or more. (healthline.com)
- Stage 4 breast cancer is considered the most advanced stage and requires the most aggressive treatment. (healthline.com)
- Even with insurance, many breast cancer survivors struggle with financial burden after treatment. (healthline.com)
- Oncologists are using the 21-gene recurrence score assay to personalize treatment for patients with early-stage, hormone receptor-positive breast cancer, including those with node-positive disease, a study published in the journal Cancer has shown. (oncologynurseadvisor.com)
- Background: Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. (diva-portal.org)
- This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer. (diva-portal.org)
- It's more likely to have spread beyond your breast at the time it's found, and there's a higher chance it will come back within the first 3 years after treatment. (webmd.com)
- Breast cancer patients (n=94) who underwent surgical treatment at several hospitals [National Hospital Organization Kyushu Cancer Center (Fukuoka, Fukuoka) Kyushu University Beppu Hospital (Beppu, Oita), Oita Prefectural Hospital (Yufu, Oita) and Takada-Chuo Hospital (Yokohama, Kanagawa), all in Japan)] between 1990 and 1999 were enrolled in the study. (spandidos-publications.com)
- Powell-Auslam is playing her last game before she receives treatment for the breast cancer. (dailybulletin.com)
- 10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment. (medworm.com)
- This study sought to evaluate local control and cosmetic results of delivering boost doses using a high-dose-rate (HDR) brachytherapy (HDRBT) in breast cancer conservative treatment. (medworm.com)
- In the future, these findings may prove significant for the assessment of breast cancer prognosis and treatment planning. (eurekalert.org)
- Impact on Risk, Prognosis and Treatment Prediction. (lu.se)
- We retrospectively investigated the clinical status of 119 women with HER-2 + locally advanced breast cancer who underwent treatment from November 2010 to July 2016, at the Guangdong Provincial Hospital of Chinese Medicine. (hindawi.com)
- A factsheet about breast cancer in the past, today, and how current research may change treatment and prevention in the future. (cancerindex.org)
- A new test may help to identify breast cancer patients with the lowest risk of death, therefore helping them to avoid unnecessarily aggressive treatment. (medicalnewstoday.com)
- Joni has been in the middle of her breast cancer treatment for eight very long months. (crosswalk.com)
- Almost eight years later, I now know that there are many treatment options and more being developed all the time. (swedish.org)
- She had a particularly nasty case of HER 2 positive breast cancer with weight loss, breathing difficulties and bone pain when we started her treatment. (swedish.org)
- The money funds breast cancer health education, screening, and treatment programs. (cancertutor.com)
- A prognosis is the doctor's best estimate of how cancer will affect someone and how it will respond to treatment. (cancer.ca)
- They both play a part in deciding on a treatment plan and a prognosis. (cancer.ca)
- Breast tumours that are 5 cm or larger are more likely to come back after treatment than smaller tumours. (cancer.ca)
- The following factors may affect prognosis for breast cancer that comes back after treatment. (cancer.ca)
- A new study reveals that treatment of male breast cancer has evolved and improved throughout the years. (news-medical.net)
- The new study sheds light on male breast cancer treatment and prognosis. (news-medical.net)
- Our study highlights unique practice patterns and factors associated with prognosis in MBC, furthering our understanding of the treatment and prognosis of MBC. (news-medical.net)
- The effectiveness of a specific treatment is demonstrated for a specific breast cancer (usually by randomized, controlled trials). (wikipedia.org)
- That treatment may not be effective in a different breast cancer. (wikipedia.org)
- Treatment algorithms rely on breast cancer classification to define specific subgroups that are each treated according to the best evidence available. (wikipedia.org)
- Each of these aspects influences treatment response and prognosis. (wikipedia.org)
- After treatment, the cancer returned last year. (nytimes.com)
- While many stage IV survivors live quite a few years, metastatic breast cancer is considered a fatal disease. (healthcentral.com)
- What is the Metastatic Breast Cancer Project? (healthcentral.com)
- Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane. (ebscohost.com)
- My name is Dr. Erin Ellis, and I have taken care of patients with metastatic breast cancer (MBC) for nearly 30 years beginning in my fellowship at the University of Chicago. (swedish.org)
- it never occurred to me that as a young woman I could actually be diagnosed with metastatic breast cancer. (swedish.org)
- Metastatic breast cancer has a less favorable prognosis. (wikipedia.org)
- Our purpose in this analysis was to examine whether intake of these marine fatty acids (EPA and DHA) were associated with prognosis in a cohort of women who had been diagnosed and treated for early stage breast cancer (n = 3,081). (greenmedinfo.com)
- Specifically, they were more likely to undergo lumpectomy (67 percent versus 48 percent), less likely to undergo modified radical mastectomy (25 percent versus 47 percent), and less likely to die of breast cancer (4 percent versus 11 percent). (redorbit.com)
- Among patients with Stage I disease, 8 patients underwent mastectomy and 13 patients underwent breast-conserving surgery (BCS). (nih.gov)
- Many doctors think that because triple-negative breast cancer is aggressive, it's best to do a mastectomy to remove the entire breast. (webmd.com)
- Often a mastectomy and breast reconstruction can be performed in the same procedure. (mdanderson.org)
- Types of surgery vary from breast-conserving surgery to mastectomy . (wikipedia.org)
- The American Cancer Society and other medical organizations recommend that women should begin receiving annual mammograms to screen for breast cancer beginning at age 40. (redorbit.com)
- The American Cancer Society and other medical organizations recommend that all women over 40 year not to avoid or delay their annual mammography screening for breast cancer. (doctortipster.com)
- It's not very common in younger women, but in this case a 17-year-old girl had to fight ovarian cancer. (wreg.com)
- In China, breast cancer is the most commonly diagnosed cancer in women. (biomedcentral.com)
- Breast cancer rarely occurs in young women. (biomedcentral.com)
- Eligible women ( n = 7,656) ages 40 to 69 years diagnosed with primary breast cancer between 1992 and 2002 were followed up until 2003. (aacrjournals.org)
- This difference existed only among women diagnosed before 1998, ages 50 to 59 years, and was strongest among stage II breast cancer patients. (aacrjournals.org)
- The participants were all women with primary breast cancer reported to this register from January 1992 through December 2002 (12,163 women), with follow-up until December 2003. (aacrjournals.org)
- The USPSTF recommends that clinicians offer to prescribe risk-reducing medications for women who are at increased risk for breast cancer, with some exceptions. (oncologynurseadvisor.com)
- On a global scale breast cancer is the most common cancer amongst women . (medindia.net)
- Nevertheless, younger women with Breast lumps are at a far greater risk for breast cancer in comparison to asymptomatic women of the same age group, and to older women. (medindia.net)
- Breast cancer mostly occurs in women over the age of 50, and the risk is especially high for women over age 60. (medindia.net)
- Breast cancer is also found to occur more often in white women than African American or Asian women. (medindia.net)
- Breast cancer is 100 times more frequent in women in comparison to men. (medindia.net)
- 16% of women between the age of 40-60 years have breast-related problems. (medindia.net)
- A 16-year breast cancer survivor, her passion is helping women through this devastating disease. (healthcentral.com)
- As a result, clinicians treating women with breast cancer frequently caution them to either avoid soy foods entirely or use them in moderation ( 2 , 5 , 6 ). (aacrjournals.org)
- Women included in this study had a median follow-up of 7.3 years from the time of enrollment. (aacrjournals.org)
- Interventions Women aged 40-49 in the mammography arm and all women aged 50-59 in both arms received annual physical breast examinations. (bmj.com)
- Results During the five year screening period, 666 invasive breast cancers were diagnosed in the mammography arm (n=44 925 participants) and 524 in the controls (n=44 910), and of these, 180 women in the mammography arm and 171 women in the control arm died of breast cancer during the 25 year follow-up period. (bmj.com)
- Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial. (bmj.com)
- In 1980 a randomised controlled trial of screening mammography and physical examination of breasts in 89 835 women, aged 40 to 59, was initiated in Canada, the Canadian National Breast Screening Study. (bmj.com)
- They gave this recommendation based on some evidence gathered and it is directed to women between 50 and 74 years who may be considered to be at average risk. (southlakeoncology.com)
- A total of 643 (actual)(504, initially proposed) postmenopausal women were randomized according to their number of years since menopause, less than 6 years or 10 years or more, to receive either oral 17B-estradiol 1 mg daily or a placebo. (clinicaltrials.gov)
- According to Contemporary Oncology , about 34 percent of women experience a distant recurrence with the average time of relapse being 2.6 years. (healthline.com)
- They were trials of women scheduled to receive five years of therapy, but we don't know if they completed their therapy. (healthline.com)
- For the study, investigators surveyed 3880 women treated for breast cancer between 2013 and 2014 who were included in the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries. (oncologynurseadvisor.com)
- Dr. Shelley Hwang, a breast surgeon at UC San Francisco, says DCIS strikes almost 70,000 American women annually and accounts for about one-fifth of all new diagnosed breast cancers. (people.com)
- Not many women do -- it only affects up to 20% of those who have breast cancer . (webmd.com)
- Still, her team concluded that "considering both breast density and age" may be key to spotting women at higher risk for an aggressive breast cancer. (ahealthyme.com)
- According to the ACS, women aged 40 to 44 "should have the choice to start annual breast cancer screening with mammograms" if they wish to do so. (ahealthyme.com)
- In its sixth year, the Breast Cancer 3-Day, a 60-mile walk that takes place over three consecutive days, will raise millions of dollars and heighten awareness of the disease affecting one in eight women in the U.S. during their lifetime. (bio-medicine.org)
- The Breast Cancer 3-Day appeals to women and men of all fitness levels who are committed to a deeper challenge in the fight against breast cancer. (bio-medicine.org)
- Breast cancer is the most common cancer among women. (springer.com)
- Breast cancer is the most frequently diagnosed cancer and accounts for 22.9% of all cancers in women worldwide[ 1 ]. (plos.org)
- In 2008, approximately 1.38 million (23%) new breast cancer cases were diagnosed in women and 458,503 deaths occurred from breast cancer, comprising 13.7% of all female cancer deaths[ 1 ]. (plos.org)
- Breast cancer is a disease of older women. (scienceblogs.com)
- As has been discussed before , for breast cancer, environment- and lifestyle-attributable causes account for a much smaller fraction of cancer diagnoses than most people believe, and 1.8% of cases of breast cancer occur in women 34 and under . (scienceblogs.com)
- Even though I am a 67-year-old woman who has no known risk factors for breast cancer , I deliberately ignored the U.S. Preventive Services Task Force's recent recommendation that women between ages 50 and 74 should have mammograms only every other year. (courant.com)
- A 2009 review for the US Preventive Services Task Force found evidence of benefit in those 40 to 70 years of age, and the organization recommends screening every two years in women 50 to 74 years old. (wikipedia.org)
- Surgical removal of both breasts is another preventative measure in some high risk women. (wikipedia.org)
- Worldwide, breast cancer is the leading type of cancer in women, accounting for 25% of all cases. (wikipedia.org)
- Breast cancer is the most common type of cancer among women, the risk of breast cancer increases with age, it is most common after the age of 50. (cancerindex.org)
- Breast cancer is currently the most common form of cancer in women, regardless of race or ethnicity. (medicalnewstoday.com)
- Overall, breast cancer ranks as the second leading cause of cancer-related death among women. (medicalnewstoday.com)
- Founded nine years ago, the non-profit raises money to help women battling breast cancer pay for school, a car and hot water for their home. (wtvr.com)
- Breast cancer will affect 1 in 8 women during their lifetime - and it is the fourth-leading cause of cancer death in the United States. (cancertutor.com)
- This helps increase your levels of Vitamin D. Research shows that postmenopausal women with the highest levels of Vitamin D had a lower risk of developing breast cancer when compared to those with the lowest levels. (cancertutor.com)
- Family history: The risk of breast cancer is higher among women who have relatives with the disease. (medicinenet.com)
- Women diagnosed with certain benign breast conditions have an increased risk of breast cancer. (medicinenet.com)
- Being overweight or obese increases the risk of breast cancer both in pre- and postmenopausal women but at different rates. (medicinenet.com)
- Women younger than 35 years of age tend to be diagnosed with more aggressive, higher grade tumours. (cancer.ca)
- Breast cancer is known as an illness that affects mostly women, but about 1 percent of all breast cancers affect men, too. (news-medical.net)
- This study has recruited over 3000 women with breast cancer diagnosed before 41 years of age and provides material for studies investigating the role of inherited genetic mutation in breast cancer risk and prognosis. (southampton.ac.uk)
- Surprisingly, about 85 percent of breast cancers occur in women who have no family history of the disease, which means that technically all women are at risk. (miaminewtimes.com)
- There are currently no known molecular targets for this subgroup of breast cancer patients and there seem to be few therapeutic options on the horizon, especially given that the development of poly (ADP ribose) polymerase and EGFR inhibitors have been thus far disappointing ( 2 ). (pnas.org)
- Dr. Neal S. Goldstein, MD, Director, Molecular Oncology and Advanced Diagnostics Laboratory of William Beaumont Hospital in Royal Oaks, Michigan says, "I prefer MammaPrint(R) because it is applicable for both ER positive and ER negative breast cancers as there is no standard determining the ER status. (bio-medicine.org)
- Kallioniemi A. Molecular signatures of breast cancer: predicting the future. (springer.com)
- Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. (springer.com)
- Paik S. Molecular profiling of breast cancer. (springer.com)
- analizar el perfil molecular de la expresi n inmunohistoqu mica en c ncer de mama ajustado por variables cl nicas e histopatol gicas y su repercusi n en la recurrencia y supervivencia de las pacientes libres de enfermedad. (medigraphic.com)
- Tsuchiya K, Reijo R, Page DC, Disteche CM. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. (medscape.com)
- For invasive breast cancers, another key factor is the molecular receptor status of the cancer cells. (mdanderson.org)
- But now this could change, as researchers from the University of California, San Francisco (UCSF) - in collaboration with scientists from various universities across Sweden - have found that a molecular test can help to predict which breast cancer patients will have the lowest risk of death. (medicalnewstoday.com)
- Population-based molecular prognosis of breast cancer by transcriptional profiling. (cdc.gov)
- Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study [published online January 11, (oncologynurseadvisor.com)
- Main outcome measure Deaths from breast cancer. (bmj.com)
- Gene expression profiling predicts clinical outcome of breast cancer. (springer.com)
- You are likely to have a very good outcome from breast reduction surgery. (medlineplus.gov)
- The authors concluded that "decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences. (oncologynurseadvisor.com)
- The take-home message is "that we need to identify patients at risk for an interval cancer and possibly screen them more frequently," said Dr. Alice Police, who helps direct breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y. (ahealthyme.com)
- Breast reduction surgery directs its intentions toward 2 primary alterations in breast habitus. (medscape.com)
- Emotional risks for this surgery may include feeling that your breasts do not look perfect. (medlineplus.gov)
- You may need mammograms or breast x-rays before surgery. (medlineplus.gov)
- Breast reduction is surgery to reduce the size of the breasts. (medlineplus.gov)
- Breast reduction surgery is done under general anesthesia . (medlineplus.gov)
- You may have a temporary loss of sensation in your breast skin and nipples after surgery. (medlineplus.gov)
- Like all surgeries, breast cancer surgery is most successful when performed by a specialist with a great deal of experience in the particular procedure. (mdanderson.org)
- Breast reconstruction may take place at the time of surgery or at a later date. (wikipedia.org)
- An animated video about the signs and symptoms of breast cancer and surgery for breast cancer - part of a series of videos about breast cancer aimed at general practitioners and their patients. (cancerindex.org)
- A prespecified subgroup analysis, however, revealed that study patients with triple-negative breast cancer and BRCA -mutations had an improved 2-year OS rate of 95% compared with 91% for noncarriers. (oncologynurseadvisor.com)
- That's important because triple-negative breast cancer is more aggressive than other forms. (webmd.com)
- Doctors aren't sure what makes you more likely to get triple-negative breast cancer. (webmd.com)
- What is the current prognosis for triple-negative breast cancer and how common is this form of cancer? (utaustinportugal.org)
- Those patients with triple negative breast cancer need more options, but perhaps new approaches in immunotherapy with pay off for this group. (swedish.org)
- The grade of the breast cancer can affect prognosis. (cancer.ca)
- CpG methylation signature predicts prognosis in breast cancer. (nih.gov)
- However, the mechanism underlying how Twist predicts prognosis is not well defined in breast cancers. (plos.org)
- Now, the new study , published in the journal CANCER , the peer-reviewed journal of the American Cancer Society, shows how MBC is treated and the researchers have identified factors tied to patient prognosis. (news-medical.net)
- About 75% of breast cancers are estrogen receptor-positive (ER-positive, or ER+). (news-medical.net)
- The primary classification of breast cancer is based mainly on the expression of the estrogen receptor, and 70-80% of breast cancers are estrogen receptor positive, and are classified as luminal. (diva-portal.org)
- In addition, a significant inverse correlation was identified between the expression levels of DNMT3A and miR‑29b in estrogen receptor‑positive breast cancer patients (P=0.027). (spandidos-publications.com)
- This study examined the characteristics and the prognosis of patients with a local recurrence occurring more than 5 years after BCT. (eur.nl)
- Although HEVs are generally restricted to lymphoid organs, evidence accumulated over the past 25 years indicates that blood vessels with HEV characteristics develop in nonlymphoid tissues in many chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel diseases, chronic gastritis, and autoimmune thyroiditis ( 15 , 18-20 ). (aacrjournals.org)
- The proposed study will overcome these limitations by using the resources of the After Breast Cancer Pooling Project (ABCPP), a collaborative project that includes four prospective cohorts of breast cancer survivors, for which we have successfully pooled and harmonized data on clinical characteristics and lifestyle factors. (labome.org)
- Although breast cancer shares certain characteristics and qualities in both genders, there are noteworthy differences. (news-medical.net)
- The current National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer do not recommend surveillance imaging for earlier detection of distant metastases, even for high-risk breast cancer patients. (clinicaltrials.gov)
- The aim of the present study was to determine the clinical significance of miR‑29b expression in primary breast cancer patients. (spandidos-publications.com)
- In the first project, we present a population-based study to predict recurrence and metastases of breast cancer using the public gene expression profiles and associated clinical data. (springer.com)
- We believe that an integrated approach combining gene expression profiles, protein expression profiles, as well as clinical information will lead to more informed clinical decision making in breast cancer intervention. (springer.com)
- Abramovitz M, Leyland-Jones B. A systems approach to clinical oncology: focus on breast cancer. (springer.com)
- Microarrays in breast cancer research and clinical practice: the future lies ahead. (springer.com)
- The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. (medsci.org)
- Yara Abdou, MD, of Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., and colleagues presented this work in a poster at the ASCO-SITC Clinical Immuno-Oncology Symposium. (mdedge.com)
- Over the 18-year period, the number of breast cancers diagnosed at Stage 0 increased by 66 percent, while the number of Stage III breast cancers decreased by 66 percent. (redorbit.com)
- In this study, we used information from a population-based breast cancer register that captures information on all breast cancers diagnosed in the Uppsala/Örebro health care region. (aacrjournals.org)
- We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. (nature.com)
- At my most recent oncology appointment, I asked my doctor if, since I'd passed 15 years, I could stop worrying. (healthcentral.com)
- She wasn't involved in the new study, which was led by Anne Marie McCarthy, a breast oncology research fellow at Massachusetts General Cancer Hospital in Boston. (ahealthyme.com)
- Dr. Steven Hancock is a Professor of Radiation Oncology at Stanford University Medical Center who has practiced at Stanford for over 30 years. (stanford.edu)